Mobile

An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequate...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-001311-30

An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate that 4 weeks of treatment with valsartan 160 mg plus HCTZ 25 mg in fixed dose combination provide an additional mean sitting diastolic blood pressure reduction in patients not adequately responding (i.e., MSDBP ≥ 90 mmHg) to 4 weeks of treatment with an angiotensin receptor blocker + HCTZ 25 mg in free combination (candesartan 32 mg plus HCTZ 25 mg).

Critère d'inclusion

  • Moderate essential hypertension (WHO grade II)

Liens